2011
DOI: 10.4292/wjgpt.v2.i3.17
|View full text |Cite
|
Sign up to set email alerts
|

Proton pump inhibitor-associated pneumonia: Not a breath of fresh air after all?

Abstract: Over the past two decades, proton pump inhibitors (PPIs) have emerged as highly effective and relatively safe agents for the treatment of a variety of gastrointestinal disorders. Unfortunately, this desirable pharmacological profile has also contributed to superfluous and widespread use in both the inpatient and outpatient settings. While generally well-tolerated, research published over the last decade has associated these agents

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
39
0
10

Year Published

2012
2012
2022
2022

Publication Types

Select...
4
1
1

Relationship

0
6

Authors

Journals

citations
Cited by 68 publications
(50 citation statements)
references
References 56 publications
1
39
0
10
Order By: Relevance
“…Tako su glavne indikacije za njihovu primenu peptički ulkus, erozivni i neerozivni refluksni ezofagitis, Zollinger-Ellisonov sindrom, infekcija izazvana bakterijom Helicobacter pylori (u okviru kombinovane terapije), kao i profilaksa stres ulkusa. Derivat benzimidazola -omeprazol prvi je uvedeni IPP osamdesetih godina prošlog veka, a danas se na tržištu nalaze i ostali: lansoprazol, rabeprazol, pantoprazol i esomeprazol (aktivni S-izomer omeprazola) [1].…”
Section: Uvodunclassified
See 4 more Smart Citations
“…Tako su glavne indikacije za njihovu primenu peptički ulkus, erozivni i neerozivni refluksni ezofagitis, Zollinger-Ellisonov sindrom, infekcija izazvana bakterijom Helicobacter pylori (u okviru kombinovane terapije), kao i profilaksa stres ulkusa. Derivat benzimidazola -omeprazol prvi je uvedeni IPP osamdesetih godina prošlog veka, a danas se na tržištu nalaze i ostali: lansoprazol, rabeprazol, pantoprazol i esomeprazol (aktivni S-izomer omeprazola) [1].…”
Section: Uvodunclassified
“…Pri tom je zabeležen porast propisivanja kako kod vanbolničkih, tako i kod bolničkih pacijenata. Rezultati tri različite studije pokazali su da je 40-71,4% bolesnika lečenih u bolnicama primalo antisekretornu terapiju ili IPP ili antagonistima H 2 receptora (AH 2 R), od toga čak 65-70% bolesnika nije imalo nijednu realnu indikaciju za njihovu primenu [1].…”
Section: Uvodunclassified
See 3 more Smart Citations